{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T22:34:56Z","timestamp":1790634896893,"version":"4.1.0"},"reference-count":141,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,8,21]],"date-time":"2014-08-21T00:00:00Z","timestamp":1408579200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"funder":[{"name":"Novartis Pharma AG, Basel, Switzerland"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","internationaljournalofcardiology.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1016\/j.ijcard.2014.08.032","type":"journal-article","created":{"date-parts":[[2014,8,12]],"date-time":"2014-08-12T08:46:13Z","timestamp":1407833173000},"page":"630-639","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":128,"title":["Natriuretic peptides and cardio-renal disease"],"prefix":"10.1016","volume":"176","author":[{"given":"Massimo","family":"Volpe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcard.2014.08.032_bb0005","author":"KDIGO"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0010","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1097\/01.hjh.0000431740.32696.cc","article-title":"2013 ESH\/ESC guidelines for the management of arterial hypertension. The task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)","volume":"31","author":"Mancia","year":"2013","journal-title":"J Hypertens"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0015","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1093\/eurheartj\/ehs104","volume":"33","author":"McMurray","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0020","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s10557-012-6424-y","article-title":"RAAS inhibitors and cardiovascular protection in large scale trials","volume":"27","author":"von Lueder","year":"2013","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0025","doi-asserted-by":"crossref","first-page":"H358","DOI":"10.1152\/ajpheart.00704.2012","article-title":"Natriuretic peptides and cGMP signaling control of energy homeostasis","volume":"304","author":"Moro","year":"2013","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0030","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1592\/phco.22.1.27.33502","article-title":"A review of vasopeptidase inhibitors: a new modality in the treatment of hypertension and chronic heart failure","volume":"22","author":"Nathisuwan","year":"2002","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0035","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/ajh.2008.174","article-title":"Natriuretic peptides: an update on bioactivity, potential therapeutic use, and implication in cardiovascular diseases","volume":"21","author":"Rubattu","year":"2008","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0040","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.pharmthera.2004.08.011","article-title":"C-type natriuretic peptide in vascular physiology and disease","volume":"105","author":"Scotland","year":"2005","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0045","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S1937-6448(08)00803-4","article-title":"Natriuretic peptides in vascular physiology and pathology","volume":"268","author":"Woodard","year":"2008","journal-title":"Int Rev Cell Mol Biol"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0050","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1161\/01.RES.0000094745.28948.4D","article-title":"Structure, regulation, and function of mammalian membrane guanylyl cyclase receptors, with a focus on guanylyl cyclase-A","volume":"93","author":"Kuhn","year":"2003","journal-title":"Circ Res"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0055","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/978-3-540-68964-5_15","article-title":"Natriuretic peptides: their structures, receptors, physiologic functions and therapeutic applications","volume":"191","author":"Potter","year":"2009","journal-title":"Handb Exp Pharmacol"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0060","doi-asserted-by":"crossref","first-page":"H17","DOI":"10.1152\/ajpheart.00684.2005","article-title":"Cardiac endocrine function is an essential component of the homeostatic regulation network: physiological and clinical implications","volume":"290","author":"Clerico","year":"2006","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0065","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1161\/01.RES.62.2.191","article-title":"Atrial stretch, not pressure, is the principal determinant controlling the acute release of atrial natriuretic factor","volume":"62","author":"Edwards","year":"1988","journal-title":"Circ Res"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0070","doi-asserted-by":"crossref","first-page":"886-93c","DOI":"10.1093\/eurheartj\/ehs262","article-title":"Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics","volume":"34","author":"Mangiafico","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0075","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.jash.2008.02.001","article-title":"Emerging roles of natriuretic peptides and their receptors in pathophysiology of hypertension and cardiovascular regulation","volume":"2","author":"Pandey","year":"2008","journal-title":"J Am Soc Hypertens"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0080","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/j.1476-5381.2012.01827.x","article-title":"Endothelial actions of atrial and B-type natriuretic peptides","volume":"166","author":"Kuhn","year":"2012","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0085","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1172\/JCI118162","article-title":"Rapid transcriptional activation and early mRNA turnover of brain natriuretic peptide in cardiocyte hypertrophy. Evidence for brain natriuretic peptide as an \u201cemergency\u201d cardiac hormone against ventricular overload","volume":"96","author":"Nakagawa","year":"1995","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0090","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/j.jacc.2012.05.049","article-title":"Human hypertension is characterized by a lack of activation of the antihypertensive cardiac hormones ANP and BNP","volume":"60","author":"Macheret","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0095","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1210\/endo.133.6.8243333","article-title":"Cytokine-induced C-type natriuretic peptide (CNP) secretion from vascular endothelial cells\u2014evidence for CNP as a novel autocrine\/paracrine regulator from endothelial cells","volume":"133","author":"Suga","year":"1993","journal-title":"Endocrinology"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0100","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1056\/NEJM199807303390507","article-title":"Natriuretic peptides","volume":"339","author":"Levin","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0105","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1517\/13543784.13.6.643","article-title":"Recent advances in natriuretic peptides in congestive heart failure","volume":"13","author":"Boerrigter","year":"2004","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0110","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1113\/jphysiol.2007.144253","article-title":"Natriuretic peptide C receptor signalling in the heart and vasculature","volume":"586","author":"Rose","year":"2008","journal-title":"J Physiol"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0115","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s00109-010-0641-2","article-title":"NPR-C: a component of the natriuretic peptide family with implications in human diseases","volume":"88","author":"Rubattu","year":"2010","journal-title":"J Mol Med"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0120","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1161\/CIRCRESAHA.113.301325","article-title":"C2238 atrial natriuretic peptide molecular variant is associated with endothelial damage and dysfunction through natriuretic peptide receptor C signaling","volume":"112","author":"Sciarretta","year":"2013","journal-title":"Circ Res"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0125","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1172\/JCI25417","article-title":"Atrial natriuretic peptide: an essential physiological regulator of transvascular fluid, protein transport, and plasma volume","volume":"115","author":"Curry","year":"2005","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0130","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1172\/JCI23360","article-title":"Vascular endothelium is critically involved in the hypotensive and hypovolemic actions of atrial natriuretic peptide","volume":"115","author":"Sabrane","year":"2005","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0135","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00109-011-0801-z","article-title":"Molecular mechanisms underlying cardiac antihypertrophic and antifibrotic effects of natriuretic peptides","volume":"90","author":"Calvieri","year":"2012","journal-title":"J Mol Med"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0140","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1042\/CS20120074","article-title":"Chronic kidney disease and vascular remodelling: molecular mechanisms and clinical implications","volume":"123","author":"Briet","year":"2012","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0145","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1016\/j.jacc.2011.06.058","article-title":"New targets to treat the structural remodeling of the myocardium","volume":"58","author":"Gonz\u00e1lez","year":"2011","journal-title":"J Am Coll Cardiol"},{"issue":"3 Pt 2","key":"10.1016\/j.ijcard.2014.08.032_bb0150","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1161\/hy09t1.096249","article-title":"Vascular remodeling in hypertension: roles of apoptosis, inflammation, and fibrosis","volume":"38","author":"Intengan","year":"2001","journal-title":"Hypertension"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0155","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.bbrc.2004.07.119","article-title":"Atrial natriuretic peptide inhibits cardiomyocyte hypertrophy through mitogen-activated protein kinase phosphatase-1","volume":"322","author":"Hayashi","year":"2004","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0160","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1007\/s00380-012-0311-0","article-title":"Atrial natriuretic peptide exerts protective action against angiotensin II-induced cardiac remodeling by attenuating inflammation via endothelin-1\/endothelin receptor A cascade","volume":"28","author":"Fujita","year":"2013","journal-title":"Heart Vessels"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0165","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1172\/JCI119883","article-title":"Nitric oxide, atrial natriuretic peptide, and cyclic GMP inhibit the growth-promoting effects of norepinephrine in cardiac myocytes and fibroblasts","volume":"101","author":"Calderone","year":"1998","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0170","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1161\/CIRCRESAHA.107.157677","article-title":"Atrial natriuretic peptide inhibits transforming growth factor beta-induced Smad signaling and myofibroblast transformation in mouse cardiac fibroblasts","volume":"102","author":"Li","year":"2008","journal-title":"Circ Res"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0175","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1161\/01.RES.0000117070.86556.9F","article-title":"B-type natriuretic peptide exerts broad functional opposition to transforming growth factor-beta in primary human cardiac fibroblasts: fibrosis, myofibroblast conversion, proliferation, and inflammation","volume":"94","author":"Kapoun","year":"2004","journal-title":"Circ Res"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0180","first-page":"246058","article-title":"Chronic C-type natriuretic peptide infusion attenuates angiotensin II-induced myocardial superoxide production and cardiac remodeling","volume":"2012","author":"Izumiya","year":"2012","journal-title":"Int J Vasc Med"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0185","doi-asserted-by":"crossref","first-page":"3404","DOI":"10.1073\/pnas.0538059100","article-title":"Significance and therapeutic potential of the natriuretic peptides\/cGMP\/cGMP-dependent protein kinase pathway in vascular regeneration","volume":"100","author":"Yamahara","year":"2003","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0190","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.jacc.2004.10.067","article-title":"C-type natriuretic peptide, a novel antifibrotic and antihypertrophic agent, prevents cardiac remodeling after myocardial infarction","volume":"45","author":"Soeki","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0195","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1586\/17446651.2.5.607","article-title":"Metabolic regulation: effects of natriuretic peptide interactions","volume":"2","author":"Birkenfeld","year":"2007","journal-title":"Expert Rev Endocrinol Metab"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0200","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1096\/fj.14.10.1345","article-title":"Natriuretic peptides: a new lipolytic pathway in human adipocytes","volume":"14","author":"Sengen\u00e8s","year":"2000","journal-title":"FASEB J"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0205","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1016\/j.jacc.2009.02.038","article-title":"Natriuretic peptides enhance the production of adiponectin in human adipocytes and in patients with chronic heart failure","volume":"53","author":"Tsukamoto","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0210","doi-asserted-by":"crossref","first-page":"e43238","DOI":"10.1371\/journal.pone.0043238","article-title":"Atrial natriuretic peptide and adiponectin interactions in man","volume":"7","author":"Birkenfeld","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0215","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.jacc.2011.05.011","article-title":"A genetic variant of the atrial natriuretic peptide gene is associated with cardiometabolic protection in the general community","volume":"58","author":"Cannone","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0220","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1042\/CS20040253","article-title":"Cardiac natriuretic peptides for cardiac health","volume":"108","author":"Rademaker","year":"2005","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0225","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1161\/CIRCHEARTFAILURE.112.000289","article-title":"Renin\u2013angiotensin blockade combined with natriuretic peptide system augmentation: novel therapeutic concepts to combat heart failure","volume":"6","author":"von Lueder","year":"2013","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0230","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1042\/bj2910083","article-title":"Hydrolysis of human and pig brain natriuretic peptides, urodilatin, C-type natriuretic peptide and some C-receptor ligands by endopeptidase-24.11","volume":"291","author":"Kenny","year":"1993","journal-title":"Biochem J"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0235","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/0026-0495(92)90303-R","article-title":"Neutral endopeptidase inhibition increases the urinary excretion and plasma levels of endothelin","volume":"41","author":"Abassi","year":"1992","journal-title":"Metabolism"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0240","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1096\/fasebj.3.2.2521610","article-title":"Neutral endopeptidase 24.11 (enkephalinase) and related regulators of peptide hormones","volume":"3","author":"Erd\u00f6s","year":"1989","journal-title":"FASEB J"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0245","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/j.1476-5381.1994.tb16185.x","article-title":"Generation by the phosphoramidon-sensitive peptidases, endopeptidase-24.11 and thermolysin, of endothelin-1 and c-terminal fragment from big endothelin-1","volume":"113","author":"Murphy","year":"1994","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0250","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/0196-9781(84)90020-2","article-title":"Hydrolysis of substance P and neurotensin by converting enzyme and neutral endopeptidase","volume":"5","author":"Skidgel","year":"1984","journal-title":"Peptides"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0255","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1042\/bj2410237","article-title":"Metabolism of neuropeptides. Hydrolysis of the angiotensins, bradykinin, substance P and oxytocin by pig kidney microvillar membranes","volume":"241","author":"Stephenson","year":"1987","journal-title":"Biochem J"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0260","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1177\/1358836X0000500108","article-title":"The endothelium \u2014 a new target for therapy","volume":"5","author":"Cooke","year":"2000","journal-title":"Vasc Med"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0265","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1161\/hc4001.097191","article-title":"Vasopeptidase inhibitors: a new therapeutic concept in cardiovascular disease?","volume":"104","author":"Corti","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0270","first-page":"49","article-title":"Vascular remodeling in hypertension: role of autocrine\u2013paracrine factors","volume":"2","author":"Gibbons","year":"1995","journal-title":"Blood Press Suppl"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0710","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/S0008-6363(01)00297-8","article-title":"Water and sodium regulation in chronic heart failure: the ole of natriuretic peptides and vasopressin","volume":"51","author":"Kalra","year":"2001","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0715","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1016\/S0735-1097(02)01903-4","article-title":"The regulation and measurement of plasma volume in heart failure","volume":"39","author":"Kalra","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0285","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0735-1097(03)00994-X","article-title":"The clinical implications of endothelial dysfunction","volume":"42","author":"Widlansky","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0290","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1161\/01.HYP.0000258532.07418.fa","article-title":"Molecular biology of the natriuretic peptide system: implications for physiology and hypertension","volume":"49","author":"Gardner","year":"2007","journal-title":"Hypertension"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0295","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1172\/JCI112172","article-title":"Effect of atrial peptides on aldosterone production","volume":"76","author":"Atarashi","year":"1985","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0300","first-page":"F863","article-title":"Effects of synthetic atrial natriuretic factor on renal function and renin release","volume":"247","author":"Burnett","year":"1984","journal-title":"Am J Physiol"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0305","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.cardiores.2004.05.004","article-title":"Interactions between the sympathetic nervous system and the cardiac natriuretic peptide system","volume":"63","author":"Luchner","year":"2004","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0310","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1161\/01.RES.60.5.747","article-title":"Vagal mediation of the effects of atrial natriuretic factor on blood pressure and arterial baroreflexes in the rabbit","volume":"60","author":"Volpe","year":"1987","journal-title":"Circ Res"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0315","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1161\/01.CIR.77.4.849","article-title":"Atrial natriuretic factor potentiates forearm reflex vasoconstriction induced by cardiopulmonary receptor deactivation in man","volume":"77","author":"Volpe","year":"1988","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0320","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1097\/00004872-200110000-00003","article-title":"Renin\u2013angiotensin\u2013sympathetic crosstalks in hypertension: reappraising the relevance of peripheral interactions","volume":"19","author":"Grassi","year":"2001","journal-title":"J Hypertens"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0325","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1146\/annurev.pharmtox.010909.105610","article-title":"Tissue renin\u2013angiotensin\u2013aldosterone systems: targets for pharmacological therapy","volume":"50","author":"Bader","year":"2010","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0330","series-title":"Hypertension: companion to Brenner and Rector's the kidney","first-page":"60","article-title":"The sympathetic nervous system in acute and chronic blood pressure elevation","author":"Izzo","year":"2005"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0335","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1161\/01.CIR.77.5.997","article-title":"Reduction of atrial natriuretic factor circulating levels by endogenous sympathetic activation in hypertensive patients","volume":"77","author":"Volpe","year":"1988","journal-title":"Circulation"},{"issue":"Suppl. S-b","key":"10.1016\/j.ijcard.2014.08.032_bb0340","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.18553\/jmcp.2007.13.s8-b.9","article-title":"The renin\u2013angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition","volume":"13","author":"Atlas","year":"2007","journal-title":"J Manag Care Pharm"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0345","first-page":"171","article-title":"The renin\u2013angiotensin\u2013aldosterone system in renal and cardiovascular disease and the effects of its pharmacological blockade","volume":"3","author":"Mac\u00eda-Heras","year":"2012","journal-title":"J Diabetes Metab"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0350","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.1681\/ASN.2006040356","article-title":"Renin\u2013angiotensin\u2013aldosterone system and progression of renal disease","volume":"17","author":"R\u00fcster","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0355","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1093\/eurheartj\/ehr253","article-title":"Therapeutic perspectives in hypertension: novel means for renin\u2013angiotensin\u2013aldosterone system modulation and emerging device-based approaches","volume":"32","author":"Unger","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0360","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1161\/CIRCULATIONAHA.106.668715","article-title":"Aldosterone and cardiovascular disease: smoke and fire","volume":"114","author":"Calhoun","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0365","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1161\/01.CIR.73.5.913","article-title":"Direct evidence from intraneural recordings for increased central sympathetic outflow in patients with heart failure","volume":"73","author":"Leimbach","year":"1986","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0370","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1161\/HYPERTENSIONAHA.108.119883","article-title":"Assessment of sympathetic cardiovascular drive in human hypertension: achievements and perspectives","volume":"54","author":"Grassi","year":"2009","journal-title":"Hypertension"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0375","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1093\/ndt\/15.11.1735","article-title":"Sympathetic overactivity in renal disease: a window to understand progression and cardiovascular complications of uraemia?","volume":"15","author":"Rump","year":"2000","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0380","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/jhh.2011.66","article-title":"The sympathetic nervous system and blood pressure in humans: implications for hypertension","volume":"26","author":"Fisher","year":"2012","journal-title":"J Hum Hypertens"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0385","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1046\/j.1523-1755.2000.00986.x","article-title":"Therapy of heart failure","volume":"57","author":"Schrier","year":"2000","journal-title":"Kidney Int"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0390","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/j.jacc.2009.05.015","article-title":"The sympathetic nervous system in heart failure physiology, pathophysiology, and clinical implications","volume":"54","author":"Triposkiadis","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0395","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1093\/eurheartj\/ehs041","article-title":"The human sympathetic nervous system: its relevance in hypertension and heart failure","volume":"33","author":"Parati","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0400","doi-asserted-by":"crossref","first-page":"725","DOI":"10.2147\/VHRM.S25270","article-title":"Arterial stiffness, central hemodynamics, and cardiovascular risk in hypertension","volume":"7","author":"Palatini","year":"2011","journal-title":"Vasc Health Risk Manag"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0405","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1001\/2012.jama.10503","article-title":"Aortic stiffness, blood pressure progression, and incident hypertension","volume":"308","author":"Kaess","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0410","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1161\/01.HYP.16.1.72","article-title":"Exaggerated natriuretic response to atrial natriuretic factor in rats developing spontaneous hypertension","volume":"16","author":"Pollock","year":"1990","journal-title":"Hypertension"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0415","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1126\/science.7839143","article-title":"Genetic decreases in atrial natriuretic peptide and salt-sensitive hypertension","volume":"267","author":"John","year":"1995","journal-title":"Science"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0420","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1161\/01.CIR.80.4.893","article-title":"Low-dose infusion of atrial natriuretic factor in mild essential hypertension","volume":"80","author":"Tonolo","year":"1989","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0425","doi-asserted-by":"crossref","first-page":"H1529","DOI":"10.1152\/ajpheart.00107.2006","article-title":"Lack of activation of molecular forms of the BNP system in human grade 1 hypertension and relationship to cardiac hypertrophy","volume":"291","author":"Belluardo","year":"2006","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0430","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1038\/ng.328","article-title":"Association of common variants in NPPA and NPPB with circulating natriuretic peptides and blood pressure","volume":"41","author":"Newton-Cheh","year":"2009","journal-title":"Nat Genet"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0435","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1373\/clinchem.2006.069575","article-title":"Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the valsartan heart failure (Val-HeFT) data","volume":"52","author":"Masson","year":"2006","journal-title":"Clin Chem"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0440","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1161\/STROKEAHA.111.629212","article-title":"Brain natriuretic peptide predicts functional outcome in ischemic stroke","volume":"43","author":"Rost","year":"2012","journal-title":"Stroke"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0445","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1161\/01.CIR.88.1.82","article-title":"Increased plasma levels of brain natriuretic peptide in patients with acute myocardial infarction","volume":"88","author":"Morita","year":"1993","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0450","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1161\/CIRCULATIONAHA.109.882241","article-title":"Relations of biomarkers of distinct pathophysiological pathways and atrial fibrillation incidence in the community","volume":"121","author":"Schnabel","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0455","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1161\/hc0302.103593","article-title":"Neutral endopeptidase is activated in cardiomyocytes in human aortic valve stenosis and heart failure","volume":"105","author":"Fielitz","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0460","doi-asserted-by":"crossref","first-page":"366","DOI":"10.2310\/6650.2005.53709","article-title":"Natriuretic peptides in acute and chronic kidney disease and during renal replacement therapy","volume":"53","author":"H\u00f6rl","year":"2005","journal-title":"J Investig Med"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0465","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1373\/clinchem.2009.128157","article-title":"B-type natriuretic peptide (BNP)\/NT-proBNP and renal function: is the controversy over?","volume":"55","author":"deFilippi","year":"2009","journal-title":"Clin Chem"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0470","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1373\/clinchem.2006.083170","article-title":"B-type natriuretic peptide concentrations predict the progression of nondiabetic chronic kidney disease: the mild-to-moderate kidney disease study","volume":"53","author":"Spanaus","year":"2007","journal-title":"Clin Chem"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0475","doi-asserted-by":"crossref","first-page":"3885","DOI":"10.1093\/ndt\/gfs365","article-title":"Plasma B-type natriuretic peptide level predicts kidney prognosis in patients with predialysis chronic kidney disease","volume":"27","author":"Yasuda","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0480","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1253\/circj.CJ-09-0834","article-title":"Plasma B-type natriuretic peptide level and cardiovascular events in chronic kidney disease in a community-based population","volume":"74","author":"Sakuma","year":"2010","journal-title":"Circ J"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0485","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1007\/s11906-011-0244-5","article-title":"M-atrial natriuretic peptide: a novel antihypertensive protein therapy","volume":"14","author":"McKie","year":"2012","journal-title":"Curr Hypertens Rep"},{"issue":"Suppl. 1","key":"10.1016\/j.ijcard.2014.08.032_bb0490","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/2050-6511-14-S1-P43","article-title":"M-atrial natriuretic peptide and nitroglycerin in experimental acute hypertensive heart failure: differential actions of two cGMP activating therapeutics","volume":"14","author":"McKie","year":"2013","journal-title":"BMC Pharmacol Toxicol"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0495","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1056\/NEJM200007273430403","article-title":"Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group","volume":"343","author":"Colucci","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0500","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1001\/jama.293.15.1900","article-title":"Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials","volume":"293","author":"Sackner-Bernstein","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0505","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1161\/01.CIR.0000159340.93220.E4","article-title":"Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure","volume":"111","author":"Sackner-Bernstein","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0510","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1100171","article-title":"Effect of nesiritide in patients with acute decompensated heart failure","volume":"365","author":"O'Connor","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0515","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.mayocp.2012.02.003","article-title":"Sustained blood pressure-lowering actions of subcutaneous B-type natriuretic peptide (nesiritide) in a patient with uncontrolled hypertension","volume":"87","author":"Cataliotti","year":"2012","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0520","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jacc.2008.02.077","article-title":"Design, synthesis, and actions of a novel chimeric natriuretic peptide: CD-NP","volume":"52","author":"Lisy","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0525","doi-asserted-by":"crossref","first-page":"13928","DOI":"10.1016\/S0021-9258(19)49658-0","article-title":"A new member of the natriuretic peptide family is present in the venom of the green mamba (Dendroaspis angusticeps)","volume":"267","author":"Schweitz","year":"1992","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0530","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.yjmcc.2011.03.013","article-title":"Dendroaspis natriuretic peptide and the designer natriuretic peptide, CD-NP, are resistant to proteolytic inactivation","volume":"51","author":"Dickey","year":"2011","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0535","doi-asserted-by":"crossref","first-page":"e52422","DOI":"10.1371\/journal.pone.0052422","article-title":"CD-NP: a novel engineered dual guanylyl cyclase activator with anti-fibrotic actions in the heart","volume":"7","author":"Martin","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0540","doi-asserted-by":"crossref","first-page":"e68346","DOI":"10.1371\/journal.pone.0068346","article-title":"Cenderitide-eluting film for potential cardiac patch applications","volume":"8","author":"Ng","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0545","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1177\/0091270009336233","article-title":"Pharmacodynamics of a novel designer natriuretic peptide, CD-NP, in a first-in-human clinical trial in healthy subjects","volume":"49","author":"Lee","year":"2009","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0550","doi-asserted-by":"crossref","first-page":"E1037","DOI":"10.1016\/S0735-1097(12)61038-9","article-title":"Initial experience with subcutaneous infusion of cenderitide in chronic heart failure patients","volume":"59","author":"Neutel","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0555","first-page":"447","article-title":"ANP and urodilatin: who is who in the kidney","volume":"11","author":"Hirsch","year":"2006","journal-title":"Eur J Med Res"},{"issue":"6 Suppl. 2","key":"10.1016\/j.ijcard.2014.08.032_bb0560","doi-asserted-by":"crossref","first-page":"S74","DOI":"10.1016\/j.cardfail.2007.06.307","article-title":"Discovery of a novel synthetic natriuretic peptide, CU-NP","volume":"13","author":"Lee","year":"2007","journal-title":"J Card Fail"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0565","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1097\/00004872-199207000-00002","article-title":"Candoxatril, a neutral endopeptidase inhibitor: efficacy and tolerability in essential hypertension","volume":"10","author":"Bevan","year":"1992","journal-title":"J Hypertens"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0570","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1097\/00004872-199304000-00011","article-title":"Chronic inhibition of endopeptidase 24.11 in essential hypertension: evidence for enhanced atrial natriuretic peptide and angiotensin II","volume":"11","author":"Richards","year":"1993","journal-title":"J Hypertens"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0575","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S0140-6736(00)02602-7","article-title":"Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial","volume":"356","author":"Rouleau","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0580","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.amjhyper.2003.09.014","article-title":"Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial","volume":"17","author":"Kostis","year":"2004","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0585","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1161\/01.CIR.0000029801.86489.50","article-title":"Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE)","volume":"106","author":"Packer","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0590","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/WOX.0b013e31817aecbe","article-title":"Angioedema","volume":"1","author":"Kaplan","year":"2008","journal-title":"World Allergy Organ J"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0595","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/sj.bjp.0707641","article-title":"Effect of bradykinin metabolism inhibitors on evoked hypotension in rats: rank efficacy of enzymes associated with bradykinin-mediated angioedema","volume":"153","author":"Fryer","year":"2008","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0600","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1177\/0091270009343932","article-title":"Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi)","volume":"50","author":"Gu","year":"2010","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0605","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1111\/j.1751-7176.2010.00358.x","article-title":"Combination angiotensin receptor blocker-neutral endopeptidase inhibitor provides additive blood pressure reduction over angiotensin receptor blocker alone","volume":"12","author":"Bloch","year":"2010","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0610","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(09)61966-8","article-title":"Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study","volume":"375","author":"Ruilope","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0615","series-title":"Oral presentation at 8th Asia-Pacific Congress of Hypertension (APCH), 24\u201327 November 2011, Taipei, Taiwan","article-title":"Efficacy and safety of three doses of LCZ696 in Asian hypertensive patients: a randomized, double-blind, placebo-controlled study","author":"Sun","year":"2011"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0620","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1161\/HYPERTENSIONAHA.113.02002","article-title":"Efficacy and safety of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Asian patients with hypertension. A randomized, double-blind, placebo-controlled study","volume":"63","author":"Kario","year":"2014","journal-title":"Hypertension"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0625","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1001\/2013.jamainternmed.34","article-title":"Comparative risk for angioedema associated with the use of drugs that target the renin\u2013angiotensin\u2013aldosterone system","volume":"172","author":"Toh","year":"2012","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0630","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1161\/01.HYP.36.4.594","article-title":"Differential control of systolic and diastolic blood pressure: factors associated with lack of blood pressure control in the community","volume":"36","author":"Lloyd-Jones","year":"2000","journal-title":"Hypertension"},{"issue":"29\u201334","key":"10.1016\/j.ijcard.2014.08.032_bb0635","first-page":"37","article-title":"Arterial stiffness: clinical relevance, measurement, and treatment","volume":"2","author":"Izzo","year":"2001","journal-title":"Rev Cardiovasc Med"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0640","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1177\/1358863X10382946","article-title":"The cardiovascular continuum extended: aging effects on the aorta and microvasculature","volume":"15","author":"O'Rourke","year":"2010","journal-title":"Vasc Med"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0645","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/S0140-6736(06)68943-5","article-title":"Evolution of hypertensive disease: a revolution in guidelines","volume":"368","author":"Williams","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0650","doi-asserted-by":"crossref","first-page":"65","DOI":"10.4330\/wjc.v3.i3.65","article-title":"Current status of aggressive blood pressure control","volume":"3","author":"Chrysant","year":"2011","journal-title":"World J Cardiol"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0655","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.amjcard.2004.04.043","article-title":"A likely explanation for the J-curve of blood pressure cardiovascular risk","volume":"94","author":"Kannel","year":"2004","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0660","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1093\/eurheartj\/ehq024","article-title":"Prediction of cardiovascular events and all-cause mortality with central haemodynamics: a systematic review and meta-analysis","volume":"31","author":"Vlachopoulos","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0665","series-title":"Poster presented at the 23rd European Meeting on Hypertension and Cardiovascular Protection, European Society of Hypertension (ESH), 14\u201317 June 2013, Milan, Italy","article-title":"The Prospective comparison of Angiotensin Receptor neprilysin inhibitor with Angiotensin receptor blocker MEasuring arterial sTiffness in the eldERly (PARAMETER) study design","author":"Williams","year":"2013"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0670","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/S0140-6736(12)61227-6","article-title":"The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial","volume":"380","author":"Solomon","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0675","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1161\/CIRCHEARTFAILURE.109.932996","article-title":"Factors associated with outcome in heart failure with preserved ejection fraction: findings from the Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-PRESERVE)","volume":"4","author":"Komajda","year":"2011","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0680","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-Neprilysin Inhibition versus Enalapril in Heart Failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0685","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.cardiores.2007.06.004","article-title":"The importance of endothelin-1 for vascular dysfunction in cardiovascular disease","volume":"76","author":"B\u00f6hm","year":"2007","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0690","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/S0140-6736(12)60825-3","article-title":"New drugs, procedures, and devices for hypertension","volume":"380","author":"Laurent","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0695","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S2213-8587(13)70029-9","article-title":"Effect on blood pressure of combined inhibition of endothelin-converting enzyme and neutral endopeptidase with daglutril in patients with type 2 diabetes who have albuminuria: a randomised, crossover, double-blind, placebo-controlled trial","volume":"1","author":"Parvanova","year":"2013","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0700","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1161\/HYPERTENSIONAHA.110.163972","article-title":"Endothelin-converting enzyme\/neutral endopeptidase inhibitor SLV338 prevents hypertensive cardiac remodeling in a blood pressure-independent manner","volume":"57","author":"Kalk","year":"2011","journal-title":"Hypertension"},{"key":"10.1016\/j.ijcard.2014.08.032_bb0705","first-page":"507","article-title":"Renoprotective effects of combined endothelin-converting enzyme\/neutral endopeptidase inhibitor SLV338 in acute and chronic experimental renal damage","volume":"57","author":"Sharkovska","year":"2011","journal-title":"Clin Lab"}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527314015411?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527314015411?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,4,14]],"date-time":"2022-04-14T03:36:34Z","timestamp":1649907394000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527314015411"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":141,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["S0167527314015411"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2014.08.032","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2014,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Natriuretic peptides and cardio-renal disease","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2014.08.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 The Author. Published by Elsevier Ireland Ltd.","name":"copyright","label":"Copyright"}]}}